EX-10.1
from 8-K
3 pages
This Waiver (This “Waiver”) Is Granted as of February [21], 2017, by Platinum-Montaur Life Sciences, LLC, a Delaware Limited Liability Company (“Platinum Montaur”) in Favor of Fluoropharma Medical, Inc., a Nevada Corporation (The “Company”). Capitalized Terms Used but Not Defined Herein Shall Have the Meaning Given to Such Term in the Purchase Agreement and the Warrant (Each, as Defined Below), as Applicable
12/34/56
EX-10.2
from 8-K
24 pages
This License Agreement (“Agreement”) Is Made as of the First Day of June 2014 (“Effective Date”), by and Between the General Hospital Corporation, D/B/a Massachusetts General Hospital, a Not-For-Profit Massachusetts Corporation, With a Principal Place of Business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”) and Fluoropharma Medical, Inc., a Delaware Corporation Having a Principal Place of Business at 8 Hillside Avenue, Suite 207, Montclair, New Jersey 07043 (“Company”), Each Referred to Herein Individually as a “Party” and Collectively as the “Parties.”
12/34/56
EX-10.1
from 8-K
24 pages
This License Agreement (“Agreement”) Is Made as of the First Day of June 2014 (“Effective Date”), by and Between the General Hospital Corporation, D/B/a Massachusetts General Hospital, a Not-For-Profit Massachusetts Corporation, With a Principal Place of Business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”) and Fluoropharma Medical, Inc., a Delaware Corporation Having a Principal Place of Business at 8 Hillside Avenue, Suite 207, Montclair, New Jersey 07043 (“Company”), Each Referred to Herein Individually as a “Party” and Collectively as the “Parties.”
12/34/56
